NervGen Pharma Past Earnings Performance
Past criteria checks 0/6
NervGen Pharma's earnings have been declining at an average annual rate of -21.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-21.4%
Earnings growth rate
-2.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -261.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NervGen Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -24 | 9 | 14 |
| 30 Jun 24 | 0 | -23 | 9 | 10 |
| 31 Mar 24 | 0 | -20 | 10 | 8 |
| 31 Dec 23 | 0 | -22 | 10 | 8 |
| 30 Sep 23 | 0 | -20 | 9 | 10 |
| 30 Jun 23 | 0 | -19 | 8 | 13 |
| 31 Mar 23 | 0 | -20 | 7 | 16 |
| 31 Dec 22 | 0 | -21 | 6 | 17 |
| 30 Sep 22 | 0 | -19 | 6 | 14 |
| 30 Jun 22 | 0 | -19 | 6 | 13 |
| 31 Mar 22 | 0 | -15 | 6 | 10 |
| 31 Dec 21 | 0 | -13 | 6 | 7 |
| 30 Sep 21 | 0 | -13 | 5 | 8 |
| 30 Jun 21 | 0 | -12 | 5 | 6 |
| 31 Mar 21 | 0 | -12 | 5 | 6 |
| 31 Dec 20 | 0 | -11 | 5 | 6 |
| 30 Sep 20 | 0 | -10 | 5 | 5 |
| 30 Jun 20 | 0 | -10 | 4 | 6 |
| 31 Mar 20 | 0 | -9 | 4 | 5 |
| 31 Dec 19 | 0 | -10 | 3 | 6 |
| 30 Sep 19 | 0 | -8 | 3 | 5 |
| 30 Jun 19 | 0 | -6 | 2 | 4 |
| 31 Mar 19 | 0 | -4 | 1 | 3 |
| 31 Dec 18 | 0 | -1 | 1 | 1 |
| 30 Sep 18 | 0 | -1 | 0 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
Quality Earnings: NGEN.F is currently unprofitable.
Growing Profit Margin: NGEN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NGEN.F is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare NGEN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NGEN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: NGEN.F has a negative Return on Equity (-261.55%), as it is currently unprofitable.